Lista de obras - Helen Rizos - Dominio Público Uruguay

A melanoma-associated germline mutation in exon 1beta inactivates p14ARF.

artículo científico publicado en 2001

A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration ⬇️

artículo científico publicado el 28 de noviembre de 2012

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

artículo científico publicado en 2015

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma

scientific article published on 29 November 2019

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA

artículo científico publicado en 2022

Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer

artículo científico publicado en 2008

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

artículo científico publicado en 2013

Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS

artículo científico publicado en 2010

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

artículo científico publicado en 2018

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

artículo científico publicado en 2014

Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

artículo científico publicado en 2017

Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy

scientific article published on 07 February 2020

Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy

scientific article published on 16 October 2020

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy

article

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

artículo científico publicado en 2015

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

artículo científico publicado en 2017

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

artículo científico publicado en 2017

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.

artículo científico publicado en 2014

Differential PAX3 functions in normal skin melanocytes and melanoma cells.

artículo científico publicado en 2011

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

artículo científico publicado en 2014

Differential expression of p16INK4a and p16beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations.

artículo científico publicado en 1997

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

artículo científico publicado en 2019

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

artículo científico publicado en 2019

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas

artículo científico publicado en 2017

Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis.

artículo científico publicado en 2005

Evaluation of commercial kits for purification of circulating free DNA

scientific article published on 29 August 2018

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

artículo científico publicado en 2017

First evidence of overlaps between HIV-Associated Dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia.

artículo científico publicado en 2010

Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF.

artículo científico publicado en 2007

Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression

artículo científico publicado en 2020

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma

artículo científico publicado en 2017

Human nevi lack distinguishing senescence traits.

artículo científico publicado en 2013

IGFBP7 is not required for B-RAF-induced melanocyte senescence

artículo científico publicado en 2010

Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

artículo científico publicado en 2014

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.

artículo científico publicado en 2015

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma

artículo científico publicado en 2014

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

scientific article published on 31 October 2018

Interferon Signaling Is Frequently Downregulated in Melanoma

artículo científico publicado en 2018

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

artículo científico publicado en 2012

Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery

artículo científico publicado en 2019

Liquid biomarkers in melanoma: detection and discovery.

artículo científico publicado en 2018

Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors

scientific article published on 22 April 2020

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma

artículo científico publicado en 2017

Melanocyte reprogramming requires chromatin and transcription remodelling

scientific article published on 03 March 2016

Membrane and cytoplasmic marker exchange between malignant neoplastic cells and fibroblasts via intermittent contact: increased tumour cell diversity independent of genetic change ⬇️

artículo científico publicado el 20 de agosto de 2012

Methylated circulating tumor DNA as a biomarker in cutaneous melanoma

scientific article published on 30 July 2020

Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors

artículo científico publicado en 2019

Monitoring Melanoma Using Circulating Free DNA

artículo científico publicado en 2019

Monitoring Oncogenic B-RAF-Induced Senescence in Melanocytes ⬇️

artículo científico publicado el 1 de enero de 2013

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor

artículo científico publicado en 2013

Mutations in theINK4a/ARFMelanoma Susceptibility Locus Functionally Impair p14ARF

artículo científico publicado en 2001

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

scientific article published on 03 June 2019

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

scientific article published on 01 July 2019

Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.

artículo científico publicado en 2009

Oncogene-induced senescence pathways in melanocytes.

artículo científico publicado en 2010

Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion

artículo científico publicado en 2012

Oncogenic B-RAFV600E Promotes Anchorage-Independent Survival of Human Melanocytes

scientific article published on 06 May 2010

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma

scholarly article by Mal Irvine published in September 2018

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.

artículo científico publicado en 2013

Oncogenic signaling in uveal melanoma

artículo científico publicado en 2018

Oncolytic virotherapy using herpes simplex virus: how far have we come?

artículo científico publicado en 2015

P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation

artículo científico publicado en 2011

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

artículo científico publicado en 2017

PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma

artículo científico publicado en 2013

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia

artículo científico publicado en 2019

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

artículo científico publicado en 2019

Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.

artículo científico publicado en 2010

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

artículo científico publicado en 2014

Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling

artículo científico publicado en 2022

Resistance to c-Kit inhibitors in melanoma: insights for future therapies

artículo científico publicado en 2014

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

artículo científico publicado en 2016

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis

artículo científico publicado en 2014

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.

artículo científico publicado en 2013

Selective loss of wild-type p16(INK4a) expression in human nevi

artículo científico publicado en 2011

Silencer of death domains controls cell death through tumour necrosis factor-receptor 1 and caspase-10 in acute lymphoblastic leukemia

artículo científico publicado en 2014

Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma

artículo científico publicado en 2019

Subfamilies of serine tRNA genes in the bovine genome ⬇️

artículo científico publicado el 1 de diciembre de 1991

Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling

artículo científico publicado en 2014

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

artículo científico

The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.

artículo científico publicado en 2017

The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function.

artículo científico publicado en 2015

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.

artículo científico publicado en 2012

The Role of Sumoylation in Senescence

artículo científico publicado en 2017

The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a

artículo científico publicado en 2009

The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

artículo científico publicado en 2014

The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired

artículo científico publicado en 2005

The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence

artículo científico publicado en 2009

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

artículo científico publicado en 2015

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

scientific article published on 20 April 2020

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma

scientific article published on 14 November 2020

Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization.

artículo científico publicado en 2000

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.

artículo científico publicado en 2014

Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours

artículo científico publicado en 2020

Wild type and melanoma-associated mutant p16INK4aproteins do not oligomerize in vivo

artículo científico publicado en 2009

p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism.

artículo científico publicado en 2007

p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors

artículo científico publicado en 2008

p16INK4a-induced senescence is disabled by melanoma-associated mutations

artículo científico publicado en 2008

Lista de obras de Helen Rizos

A melanoma-associated germline mutation in exon 1beta inactivates p14ARF.

A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration ⬇️

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA

Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy

Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.

Differential PAX3 functions in normal skin melanocytes and melanoma cells.

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Differential expression of p16INK4a and p16beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations.

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas

Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis.

Evaluation of commercial kits for purification of circulating free DNA

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

First evidence of overlaps between HIV-Associated Dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia.

Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF.

Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma

Human nevi lack distinguishing senescence traits.

IGFBP7 is not required for B-RAF-induced melanocyte senescence

Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

Interferon Signaling Is Frequently Downregulated in Melanoma

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery

Liquid biomarkers in melanoma: detection and discovery.

Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma

Melanocyte reprogramming requires chromatin and transcription remodelling

Membrane and cytoplasmic marker exchange between malignant neoplastic cells and fibroblasts via intermittent contact: increased tumour cell diversity independent of genetic change ⬇️

Methylated circulating tumor DNA as a biomarker in cutaneous melanoma

Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors

Monitoring Melanoma Using Circulating Free DNA

Monitoring Oncogenic B-RAF-Induced Senescence in Melanocytes ⬇️

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor

Mutations in theINK4a/ARFMelanoma Susceptibility Locus Functionally Impair p14ARF

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.

Oncogene-induced senescence pathways in melanocytes.

Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion

Oncogenic B-RAFV600E Promotes Anchorage-Independent Survival of Human Melanocytes

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.

Oncogenic signaling in uveal melanoma

Oncolytic virotherapy using herpes simplex virus: how far have we come?

P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling

Resistance to c-Kit inhibitors in melanoma: insights for future therapies

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.

Selective loss of wild-type p16(INK4a) expression in human nevi

Silencer of death domains controls cell death through tumour necrosis factor-receptor 1 and caspase-10 in acute lymphoblastic leukemia

Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma

Subfamilies of serine tRNA genes in the bovine genome ⬇️